Sign in
Taking people in United StatesNo phase

Testing a Changed Glucose Sensor in Adults With Diabetes

Tests a modified glucose sensor's safety and accuracy in adults with diabetes.

Key facts

Who runs it
Senseonics, Inc.
Where
Escondido, Renton, San Antonio, and Walnut Creek, United StatesSee the 4 sites
Trial code
Registry title
ROME GS System Study
Status
Recruiting
People taking part
60 people, planned
Started
12 Feb 2026
Expected to end
Dec 2028
Type of study
Interventional
Treatments tested
  • Continuous Glucose Monitoring System
Record updated
21 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have had diabetes for at least 1 year. It tests a changed ROME GS Sensor against the Eversense 365 Sensor.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Clinically confirmed diabetes mellitus for at least 1 year.
Earlier treatment
People using commercial skin-worn glucose monitors (for example Dexcom G6/G7 or Abbott Libre) can join. Use of the approved Eversense CGM System is not allowed.

Main reasons for not taking part

  • Severe low blood sugar without a clear cause, or diabetic ketoacidosis needing emergency or hospital care, in the previous 6 months
  • Pregnant or breastfeeding women, or women planning pregnancy or not using birth control
  • Serious heart problems, or a stroke or heart attack within 6 months
  • History of hepatitis B, hepatitis C or HIV
  • Another active implanted device, or a condition likely to need an MRI

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Subjects meeting all of the following inclusion criteria will be included in this study:
  • Subjects ≥18 years of age
  • Clinically confirmed diagnosis of diabetes mellitus for ≥1 year
  • Subject has signed an informed consent form (ICF) and is willing to comply with protocol requirements

Who cannot take part

  • History of unexplained severe hypoglycemia in the previous 6 months. Severe hypoglycemia is defined as hypoglycemia resulting in loss of consciousness or seizure
  • History of diabetic ketoacidosis requiring emergency room visit or hospitalization in the previous 6 months
  • Currently receiving (or likely to need during the study period): immunosuppressant therapy; chemotherapy; anticoagulant/antithrombotic therapy (excluding aspirin); topical glucocorticoids over sensor site only; antibiotics for chronic infection (e.g. osteomyelitis, endocarditis)
  • Participation in another clinical investigation (drug or device) within 2 weeks prior to screening or intent to participate during study period
  • A condition preventing or complicating the placement, operation or removal of the Sensor or wearing of transmitter, including upper extremity deformities or skin condition
  • History of hepatitis B, hepatitis C, or HIV
  • History of adrenal insufficiency
  • A condition requiring or likely to require magnetic resonance imaging (MRI)
  • Known topical or local anesthetic allergy
  • Known allergy to glucocorticoids
  • Any condition that in the investigator's opinion would make the subject unable to complete the study or would make it not in the subject's best interest to participate in the study. Conditions include but are not limited to psychiatric conditions, known current or recent alcohol abuse or drug abuse by subject history, a condition that may increase the risk of induced hypoglycemia or risk related to repeated blood testing. Investigator will supply rationale for exclusion
  • The presence of another active implanted device* *An example of an active implanted device includes but is not limited to an implantable defibrillator. Passive implantable devices are allowed. An example of a passive implantable device includes, but is not limited to, a cardiac stent. The use of commercial transcutaneous CGM devices (e.g. Dexcom G6/G7 CGM and Abbott Libre) are allowed and not exclusionary. Note that FDA-approved Eversense CGM System (not study provided) use will not be allowed
  • Symptomatic coronary artery disease; unstable angina; myocardial infarction, transient ischemic attack or stroke within 6 months; uncontrolled hypertension (systolic>160 mm HG or diastolic >100 mm Hg at time of screening); current congestive heart failure; history of cardiac arrhythmia (benign PACs and PVCs allowed). Subjects with asymptomatic coronary artery disease (e.g. CABG, stent placement or angioplasty) may participate if negative stress test within 1 year prior to screening and written clearance from Cardiologist documented
  • Current treatment for a seizure disorder unless written clearance by neurologist to participate in study
  • Female subjects of childbearing capacity (defined as of childbearing age and as not surgically sterile or not menopausal for ≥ 1 year) who are lactating or pregnant, intending to become pregnant, or not practicing birth control during the course of the study
  • Subjects meeting any of the following exclusion criteria at the time of screening will be excluded from this study:
  • Subjects with gastroparesis
  • Hematocrit <38% or >60% at screening

Where in United States

  • Headlands Research - AMCR InstituteEscondido, United StatesContact: Jenine Yager Stone, PhD, MSN, FNP-CTaking people
  • Rainier Clinical Research CenterRenton, United StatesContact: Tina MitchellTaking people
  • Flourish Research San AntonioSan Antonio, United StatesContact: Shelbie MartinTaking people
  • Flourish Research - Diablo Clinical ResearchWalnut Creek, United StatesContact: Catherine MorimotoNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this clinical investigation is to demonstrate that the proposed physical changes to the ROME GS Sensor do not have any adverse impact on safety and performance when compared to the Eversense 365 Sensor.

The group in the trial

  • Continuous Glucose Monitoring DeviceTreatment being tested

    Eversense 365 Continuous Glucose Monitoring System and ROME GS System

    Treatment: Continuous Glucose Monitoring System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
ROME GS System Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of the ROME GS System
Plain-language title
Testing a Changed Glucose Sensor in Adults With DiabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
21 April 2026